naa a22 4500 510763332 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130901xx s 000 0 eng 10.1007/s12094-013-1034-0 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1034-0 Proteomic biomarkers in lung cancer [Elektronische Daten] [M. Pastor, A. Nogal, S. Molina-Pinelo, A. Carnero, L. Paz-Ares] The correct understanding of tumour development relies on the comprehensive study of proteins. They are the main orchestrators of vital processes, such as signalling pathways, which drive the carcinogenic process. Proteomic technologies can be applied to cancer research to detect differential protein expression and to assess different responses to treatment. Lung cancer is the number one cause of cancer-related death in the world. Mostly diagnosed at late stages of the disease, lung cancer has one of the lowest 5-year survival rates at 15%. The use of different proteomic techniques such as two-dimensional gel electrophoresis (2D-PAGE), isotope labelling (ICAT, SILAC, iTRAQ) and mass spectrometry may yield new knowledge on the underlying biology of lung cancer and also allow the development of new early detection tests and the identification of changes in the cancer protein network that are associated with prognosis and drug resistance. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Lung cancer nationallicence Proteomics nationallicence Diagnostic biomarkers nationallicence Prognostic biomarkers nationallicence Predictive biomarkers nationallicence Pastor M. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut Nogal A. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut Molina-Pinelo S. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut Carnero A. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut Paz-Ares L. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 671-682 1699-048X 15:9<671 2013 15 12094 https://doi.org/10.1007/s12094-013-1034-0 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1034-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pastor M. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut NATIONALLICENCE 700 1- Nogal A. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut NATIONALLICENCE 700 1- Molina-Pinelo S. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut NATIONALLICENCE 700 1- Carnero A. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut NATIONALLICENCE 700 1- Paz-Ares L. Servicio de Oncología Médica, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Av. Manuel Siurot s/n, 41013, Seville, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 671-682 1699-048X 15:9<671 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer